Liraglutide common uses, half-life, side effects and more

Liraglutide is a once-daily GLP-1 receptor agonist injected under the skin. It is approved under two brand names for two different jobs. Victoza treats type 2 diabetes and lowers heart risk in people who already have heart disease. Saxenda is used alongside diet and exercise to reduce body weight. Generic liraglutide is now approved for both uses and several versions are on the market. Powder sold by research vendors and compounded vials are not the same product as the approved pen and are not held to the same standard.

• Blood sugar control in type 2 diabetes from age 10
• Lowering heart attack and stroke risk in type 2 diabetes with existing heart disease
• Weight reduction in adults with obesity or a weight-related illness
• Adolescent weight management from age 12 above 60 kg
• A daily option when a weekly injection is not tolerated or not available

Once daily

Victoza starts at 0.6 mg under the skin once daily for one week, then moves to 1.2 mg once daily. It goes to 1.8 mg only when blood sugar needs more control. The diabetes ceiling is 1.8 mg. Saxenda climbs by 0.6 mg each week through 1.2 mg, 1.8 mg, and 2.4 mg to a 3.0 mg daily target. Adults who cannot tolerate 3.0 mg are told to stop rather than settle lower. Adolescent escalation may take eight weeks and may finish at 2.4 mg. The 0.6 mg starting dose does not control blood sugar on its own and exists only to blunt nausea.

• Inject under the skin of the abdomen, thigh, or upper arm at any time of day without regard to meals
• Rotate sites within the same region because repeated use of one spot can leave amyloid deposits under the skin
• The Victoza pen only delivers 0.6 mg, 1.2 mg, or 1.8 mg so a schedule built for Saxenda cannot be run on it
• Both products restart at 0.6 mg after more than three days missed and only Saxenda then repeats its full weekly climb
• Saxenda is stopped in adults who have not lost 4 percent of their body weight by 16 weeks

About 13 hours after subcutaneous injection. Steady state arrives after roughly three days of daily use. The figure holds across every approved dose from 0.6 mg to 3.0 mg. The long tail comes from slow release out of the injection site rather than from slow clearance.

Unused pens stay refrigerated between 2 and 8 degrees Celsius. A pen in use may sit refrigerated or at room temperature up to 30 degrees for 30 days. Do not freeze it. Remove the needle after each injection and keep the pen away from heat and light.

• Nausea is by far the most common effect and reached 39 percent at the 3 mg weight dose against 14 percent on placebo
• Diarrhea, constipation, and vomiting follow and all run well above placebo
• Headache and dizziness were recorded but sat close to placebo rates
• Gallstones, pancreatitis, and kidney injury from dehydration are uncommon and documented
• Low blood sugar becomes likely when the drug is combined with insulin or a sulfonylurea
• Constipation severe enough to block the bowel has been reported after marketing

Liraglutide is a near copy of human GLP-1 sharing 97 percent of its sequence. Arginine replaces the lysine at position 34 and a palmitic fatty acid hangs off position 26 through a glutamic acid spacer. That fatty acid binds it to blood protein and shields it from the enzymes that break down natural GLP-1. It also makes the molecule clump together in solution. That clumping is the proposed reason absorption from the injection site is slow. It raises insulin at the receptor only when blood sugar is already high and lowers glucagon on the same terms. It delays stomach emptying slightly and briefly. Animal work places part of the appetite effect in the hypothalamus and no equivalent human pathway has been shown. Weight loss comes from eating less rather than from burning more.

The human evidence base is large. A cardiovascular outcome trial randomized 9,340 adults with type 2 diabetes and high heart risk on doses up to 1.8 mg. Major cardiovascular events fell from 14.9 percent on placebo to 13.0 percent on liraglutide over a median 3.8 years. The pivotal obesity trial gave 3.0 mg daily for 56 weeks and produced about 8 percent weight loss against 2.6 percent on placebo. Separate trials support use in children aged 10 and older with type 2 diabetes and in adolescents with obesity. A head-to-head trial against weekly semaglutide favored semaglutide at 15.8 percent against 6.4 percent of body weight. Drug assignment there was not blinded and far more people quit the liraglutide arm. Adolescents regained weight faster than placebo after stopping. No head-to-head trial against tirzepatide exists.

• A boxed warning covers thyroid C-cell tumors found in rats and mice and it is contraindicated with a personal or family history of medullary thyroid cancer or MEN type 2
• Saxenda labeling says not to combine it with any other GLP-1 receptor agonist
• Gray-market powder has no fixed strength and a dosing chart written for one vial size and water volume gives the wrong syringe units for another
• Stop and seek care for severe abdominal pain, persistent vomiting, or signs of an allergic reaction
• Delayed stomach emptying has left food in the stomach before anesthesia and no proven way to prevent that is known
• Saxenda should stop when pregnancy is recognized and Victoza needs an individual risk judgment